Physician profile
Kimberly Sharay Smith
NPI 1932798667
$10,299.68
in general payments reported to CMS, 2019-2025
23 companies · $3,581 in 2025
The $3,581 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $234 · 2023: $960 · 2024: $5,277 · 2025: $3,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,943 · Food and Beverage: $3,137 · Travel and Lodging: $996 · Education: $518 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,942.98 |
| Food and Beverage | $3,136.70 |
| Travel and Lodging | $995.86 |
| Education | $517.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,645.45 | 2024-2025 | Ojjaara |
| Novartis Pharmaceuticals Corporation | $1,493.56 | 2024-2025 | |
| Sobi, INC | $1,436.92 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,241.30 | 2023-2024 | Pomalyst |
| Celgene Corporation | $1,114.91 | 2021-2025 | Reblozyl |
| Incyte Corporation | $842.24 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Otsuka America Pharmaceutical, INC. | $201.96 | 2022-2024 | Rexulti, Abilify Maintena |
| Jazz Pharmaceuticals INC. | $148.66 | 2024 | |
| Syndax Pharmaceuticals, INC. | $128.05 | 2025 | Revuforj |
| Beone Medicines USA, INC. | $127.59 | 2025 | Brukinsa |
| Beigene USA, INC. | $124.73 | 2023 | Brukinsa |
| Kite Pharma, INC. | $123.53 | 2025 | |
| Epizyme, INC. | $121.84 | 2021 | |
| Genmab U.S., INC. | $110.00 | 2023 | Epkinly |
| Alexion Pharmaceuticals, INC. | $100.70 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81.52 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.62 | 2025 | |
| Geron Corporation | $61.47 | 2025 | Rytelo |
| Virtus Pharmaceuticals LLC | $44.86 | 2024 | Levorphanol Tartrate |
| Servier Pharmaceuticals LLC | $24.69 | 2025 | |
| Tersera Therapeutics LLC | $24.56 | 2023 | Zoladex |
| Astrazeneca Pharmaceuticals Lp | $21.84 | 2024 | Enhertu |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.68 | 2024 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.